Iressa/Docetaxel in Non-Small-Cell Lung Cancer
This study has been withdrawn prior to enrollment.
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
First received: October 24, 2002
Last updated: July 27, 2012
Last verified: July 2012
Patients will receive 250 mg Iressa by mouth daily each day while on this study. Patients will also receive docetaxel 30 mg/m2 by by vein (IV) on day 1 weekly for the first 3 weeks of each course of therapy. A course of therapy is 4 weeks. Patients will not receive docetaxel during week 4. A maximum of 8 full cycles of docetaxel plus Iressa are planned. Patients may continue on daily Iressa until progressive disease and/or unacceptable toxicity.
Non-small Cell Lung Cancer
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
||A Phase II Study of ZD1839 (Iressa), Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, in Combination With Docetaxel in Patients With Recurrent or Metastatic Advanced Non-Small Cell Lung Cancer
Primary Outcome Measures:
- Patient Response Rate to Iressa/Docetaxel [ Time Frame: 4 weeks cycles ] [ Designated as safety issue: No ]
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||July 2003 (Final data collection date for primary outcome measure)
Experimental: Iressa + Docetaxel
250 mg by mouth daily each day for 4 weeks.
30 mg/m2 by IV on day 1 weekly for the first 3 weeks of each 4 week course.
Other Name: Taxotere
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Pathologically confirmed non-small cell lung cancer.
- Measurable, evaluable disease outside of a radiation port.
- ECOG performance status 0-2.
- Adequate hematologic function as defined by an absolute neutrophil count >= 1,500/mm3, a platelet count >= 100,000/mm3, a WBC >= 3,000/ mm3, and a hemoglobin level of >= 9 g/dl.
- One prior chemotherapy regimen. This may include chemoradiation treatment.
- Disease progression or recurrence within 6 months of last dose of chemotherapy in first chemotherapy regimen.
- At least a 2-week recovery from prior therapy toxicity.
- Signed informed consent.
- Prior CNS involvement by tumor are eligible if previously treated and clinically stable for two weeks after completion of treatment.
- Prior Iressa or other EGFR inhibiting agents
- Prior docetaxel therapy
- Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ.
- Any unresolved chronic toxicity greater than CTC grade 2 from previous anticancer therapy.
- Incomplete healing from previous oncologic or other major surgery.
- Concomitant use of phenytoin, carbamazepine, barbiturates, rifampicin, St John's Wort, anti-coagulants.
- Absolute neutrophil counts less than 1500 x 109/liter (L) or platelets less than 100,000x 109/liter (L).
- Serum bilirubin greater than 1.25 times the upper limit of reference range (ULRR).
- In the opinion of the investigator, any evidence of severe or uncontrolled systemic disease, (e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal disease).
- A serum creatinine >= 1.5 mg/dl and calculated creatinine clearance <= 60 cc/minute.
- Alanine amino transferase (ALT) or aspartate amino transferase (AST) greater than 2.5 times the ULRR if no demonstrable liver metastases or greater than 5 times the ULRR in the presence of liver metastases.
- Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the trial.
- Pregnancy or breast feeding
- The patient has uncontrolled seizure disorder, active neurological disease, or Grade >= 2 neuropathy
- The patient has received any investigational agent(s) within 30 days of study entry.
- The patient has signs and symptoms of keratoconjunctivitis sicca or incompletely treated eye infection.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00048087
|UT MD Anderson Cancer Center
|Houston, Texas, United States, 77030 |
M.D. Anderson Cancer Center
||Edward S. Kim, MD, BS
||UT MD Anderson Cancer Center
No publications provided
||M.D. Anderson Cancer Center
History of Changes
|Other Study ID Numbers:
|Study First Received:
||October 24, 2002
||July 27, 2012
||United States: Food and Drug Administration
Keywords provided by M.D. Anderson Cancer Center:
Non-small cell lung cancer
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on April 26, 2015
Carcinoma, Non-Small-Cell Lung
Neoplasms by Site
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Molecular Mechanisms of Pharmacological Action